Related search

Cisplatin Versus Carboplatin in Combination With Paclitaxel as Neoadjuvant Regimen for Triple Negative Breast Cancer

OncoTargets and Therapy
OncologyPharmacology
2017English

Advances in Small-Molecule Drug Discovery for Triple-Negative Breast Cancer

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2015English

Triple-Negative Breast Cancer

2018English

Prevalence of Papillomaviruses, Polyomaviruses, and Herpesviruses in Triple-Negative and Inflammatory Breast Tumors From Algeria Compared With Other Types of Breast Cancer Tumors

PLoS ONE
Multidisciplinary
2014English

Genes Associated With Histopathologic Features of Triple Negative Breast Tumors Predict Molecular Subtypes

Breast Cancer Research and Treatment
Cancer ResearchOncology
2016English

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Current Perspectives on Genotype Classification and Individualized Drug Targeting in Triple-Negative Breast Cancer

Tropical Journal of Pharmaceutical Research
PharmacologyPharmaceutical Science
2018English

Pathological Response in a Triple Negative Breast Cancer Cohort Treated With Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

Clinical Cancer Research
Cancer ResearchOncology
2018English

miR-134 in Extracellular Vesicles Reduces Triple-Negative Breast Cancer Aggression and Increases Drug Sensitivity

Oncotarget
Oncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy